NCT06708637 - Ocular Safety and Usability Study for FYB203 PFS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions

Age-Related Macular DegenerationBranch Retinal Vein Occlusion with Macular EdemaCentral Retinal Vein Occlusion with Macular EdemaDiabetic Macular EdemaDiabetic Retinopathy

Interventions

DRUG

FYB203 2 mg (0.05 mL of 40 mg/mL)

IVT administration of FYB203 in a PFS

Trial Locations (4)

90807

Research Site, Long Beach

92374

Research Site, Redlands

95008

Research Site, Campbell

97401

Research Site, Eugene